Article Abstract

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

Authors: Federica Recine, Cora N. Sternberg


The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer.